There are several risks associated with the use of percutaneous AngioJet thrombectomy, none of which are common, but all of which require some knowledge of the issues to prevent complications.
Although the use of primary angioplasty in the acute myocardial infarction (AMI) setting has been shown to achieve TIMI 3 flow in the majority of patients, there are still some instances in which ...
Catheter used to treat deep vein thrombosis to be commercialized in U.S. and Europe MARLBOROUGH, Mass., Boston Scientific has received United States (U.S.) Food and Drug Administration (FDA) approval ...
Boston Scientific ($BSX) announced simultaneous approval to market its AngioJet ZelanteDVT thrombectomy catheter for treating deep vein thrombosis in the U.S., Europe ...
1) LMCA: distal 40% lesion. 2) LAD: diffusely atherosclerotic, but unobstructed. 3) LCX: ostial 80% lesion, but there was TIMI 3 flow . 4) RCA: a large vessel and completely occluded proximally soon ...
SAN FRANCISCO (MarketWatch) -- Possis Medical Inc. said Monday it has received marketing approval from the Food and Drug Administration for its AngioJet Ultra Thrombectomy System, the next-generation ...
Boston Scientific Corporation BSX is in the process of conducting a Medical Device Correction of certain AngioJet Ultra Consoles, which were shipped to customers without the required operator’s manual ...
Background A 43-year-old African-American female (gravida 5 para 0) with an 8-week intrauterine pregnancy presented to the emergency room with crampy abdominal pain, shortness of breath, and shoulder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results